{
    "nctId": "NCT00659568",
    "briefTitle": "Metformin and Temsirolimus in Treating Patients With Metastatic or Unresectable Solid Tumor or Lymphoma",
    "officialTitle": "A Phase I Study of Temsirolimus in Combination With Metformin in Advanced Solid Tumours",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Endometrial Cancer, Kidney Cancer, Lung Cancer, Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 28,
    "primaryOutcomeMeasure": "Maximum tolerated dose and recommended phase II dose of metformin hydrochloride when administered with temsirolimus",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically confirmed malignancy, including any of the following types:\n\n  * Renal cell\n  * Endometrial\n  * Breast\n  * Small cell lung carcinoma\n  * Lymphoma\n* Metastatic or unresectable disease for which standard curative or palliative measures do not exist or are no longer effective\n* Measurable disease according to RECIST criteria\n* No unstable primary CNS tumors or metastases\n\nPATIENT CHARACTERISTICS:\n\nInclusion criteria:\n\n* ECOG performance status (PS) 0-2 or Karnofsky PS 60-100%\n* Life expectancy \\> 12 weeks\n* Absolute neutrophil count \u2265 1.5 x 10\\^9/L\n* Platelets \u2265 100 x 10\\^9/L\n* AST \u2264 2.5 times upper limit of normal (ULN)\n* Serum creatinine \u2264 ULN\n* Serum bilirubin \u2264 1.5 times ULN\n* Negative pregnancy test\n* Fertile patients must use effective contraception\n* Able to understand and willing to sign a written informed consent document\n\nExclusion criteria:\n\n* Allergies to or a history of allergic reactions attributed to any other compound of similar chemical or biologic composition to temsirolimus or metformin\n* Diabetes mellitus (type I or II)\n* Uncontrolled hypertriglyceridemia (triglyceride levels \\> 10 mmol/L)\n* History of lactic acidosis\n* Inability to swallow or digest oral medications\n* Uncontrolled intercurrent illness including, but not limited to, any of the following:\n\n  * Uncontrolled hypertension\n  * Ongoing or active infection\n  * Symptomatic congestive heart failure\n  * Unstable angina pectoris\n  * Cardiac arrhythmia\n  * Psychiatric illness/social situation that would limit compliance with study requirements\n* Significant traumatic injury within 21 days prior to treatment\n\nPRIOR CONCURRENT THERAPY:\n\nInclusion criteria:\n\n* Recovered from all prior therapy\n* At least 4 weeks since prior chemotherapy or radiotherapy (6 weeks for carmustine or mitomycin C) except low-dose, non-myelosuppressive radiotherapy\n* No limitation on other prior therapy\n* Concurrent low-dose anticoagulant (i.e., warfarin) allowed provided INR \u2264 1.1 times ULN\n* Concurrent full-dose anticoagulant (i.e., warfarin) allowed provided INR is within institutional therapeutic range (usually 2.0-3.0)\n\nExclusion criteria:\n\n* Major surgery within the past 21 days\n* Prior temsirolimus (or other known inhibitors of mammalian target of rapamycin) or metformin\n* Concurrent combination antiretroviral therapy for HIV-positive patients\n* Concurrent enzyme-inducing anti-epileptic drugs (EIAEDs) (e.g., phenytoin, carbamazepine, or phenobarbital) or other CYP3A4 inducer (e.g., rifampin or Hypericum perforatum \\[St. John's wort\\])\n* Concurrent investigational or commercial agents or therapies to treat the patient's malignancy\n* Other concurrent investigational agents other than temsirolimus or metformin",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}